Prevention and treatment of Epstein-Barr virus-associated lymphoproliferative disorders in recipients of bone marrow and solid organ transplants.
Meijer
Ellen
E
Department of Haematology, University Medical Centre, Utrecht, The Netherlands. emeijer@digd.azu.nl
Dekker
Adriaan W
AW
Weersink
Annemarie J L
AJ
Rozenberg-Arska
Maja
M
Verdonck
Leo F
LF
D000970:Antineoplastic Agents / Q000627:therapeutic use; D000998:Antiviral Agents / Q000627:therapeutic use; D001402:B-Lymphocytes / Q000276:immunology; D016026:Bone Marrow Transplantation / Q000009:adverse effects; D020031:Epstein-Barr Virus Infections / Q000150:complications / Q000517:prevention & control / Q000628:therapy*; D005544:Forecasting; D006801:Humans; D007167:Immunotherapy / Q000379:methods; D016898:Interferon-alpha / Q000627:therapeutic use; D015850:Interleukin-6 / Q000627:therapeutic use; D008232:Lymphoproliferative Disorders / Q000517:prevention & control / Q000628:therapy* / Q000821:virology; D013601:T-Lymphocytes / Q000276:immunology; D014180:Transplantation / Q000009:adverse effects*
D000970:Antineoplastic Agents; D000998:Antiviral Agents; D016898:Interferon-alpha; D015850:Interleukin-6